Peter Kolchinsky portfolio, Q1 2026

RA Capital Management · 13F for the quarter ending Mar 31, 2026

For Q1 2026, RA Capital Management reported $9.4B across 85 US-listed positions, led by ASND (24.9%), PCVX (7.1%) and RYTM (6.1%). Compared with its filing for Q4 2025, Peter Kolchinsky opened 24 new positions, added to 17, reduced 2 and sold out of 10; 42 positions did not change.

The largest purchase was a new position in SGP ($207.8M); the largest sale, the sale of the whole position in Cidara Therapeutics Inc ($743.4M).

Reported value
$9.4B
Positions
85
In the top 10
61%
Filed
May 15
2026

Key facts

13F portfolio value
$9.4BQ1 2026
Positions
85
Largest holding
ASND 24.9%
New positions
24
Sold out
10
Filed
May 15, 2026

Holdings as of (Q1 2026), filed with the SEC on . Changes are measured against the filing for Dec 31, 2025. Every tracked investor's Q1 2026 13F.

Bought and sold in Q1 2026

Peter Kolchinsky: buys and sells in Q1 2026
StockMoveSharesSizeOf portfolio
Cidara Therapeutics Incno ticker on file
▼ Sold out−3.37M$743.4M7.88%
Avidity Biosciences Incno ticker on file
▼ Sold out−8.64M$623.3M6.60%
Spyglass Pharma IncSGP▲ New+8.02M$207.8M2.20%
Zai Lab LtdZLAB▲ New+5.71M$107.4M1.14%
Sarepta Therapeutics IncSRPT▲ New+3.9M$84.9M0.90%
Dianthus Therapeutics IncDNTH▲ Added 62%+1M$83.9M0.89%
Arcellx Incno ticker on file
▼ Sold out−1.27M$82.6M0.88%
Belite Bio IncBLTE▼ Sold out−432.48K$69.2M0.73%
Nuvalent Incno ticker on file
▲ Added 35%+654.09K$67M0.71%
Wave Life Sciences LtdWVE▲ Added 48%+8.77M$63.6M0.67%
Damora Therapeutics IncDMRA▲ New+2.4M$62.1M0.66%
Xencor IncXNCR▲ New+4.9M$59.1M0.63%
Vaxcyte IncPCVX▲ Added 7.0%+750K$43.6M0.46%
Invivyd IncIVVD▼ Sold out−17.12M$42.3M0.45%
Century Therapeutics IncIPSC▲ New+17.75M$40.1M0.43%
Disc Medicine IncIRON▲ Added 24%+474.09K$30.3M0.32%
Mirum Pharmaceuticals IncMIRM▲ New+318.55K$29.4M0.31%
Bioage Labs IncBIOA▲ New+1.65M$28.9M0.31%
Aktis Oncology IncAKTS▲ New+1.5M$26.9M0.28%
Alx Oncology Holdings IncALXO▲ New+13.01M$26.1M0.28%
Aclaris Therapeutics IncACRS▲ New+6.8M$25.5M0.27%
Solid Biosciences IncSLDB▲ Added 61%+3.53M$25.4M0.27%
Travere Therapeutics IncTVTX▲ New+746.84K$22.2M0.24%
Relmada Therapeutics IncRLMD▲ New+2.95M$20.5M0.22%
Bright Minds Biosciences IncDRUG▲ New+265K$19.3M0.20%
Sutro Biopharma IncSTRO▲ New+715.31K$17.8M0.19%
Anteris Technologies GlobalAVR▲ New+3M$16.7M0.18%
Onkure Therapeutics Inc-AOKUR▲ New+4M$16.6M0.18%
Design Therapeutics IncDSGN▲ Added 103%+1.51M$16.1M0.17%
Acumen Pharmaceuticals IncABOS▲ Added 41%+6.06M$14.3M0.15%
Medline IncMDLN▼ Sold out−335K$14.1M0.15%
Helix Acquisition CorpHLXC▲ New+1.25M$12.7M0.13%
Atrium Therapeutics IncRNA▲ New+864.1K$11.6M0.12%
Contineum Therapeutics IncCTNM▼ Reduced 41%−883.7K$11.5M0.12%
Hinge Health IncHNGE▲ Added 355%+284.5K$11M0.12%
Karyopharm Therapeutics IncKPTI▲ New+1.92M$10.7M0.11%
Mineralys Therapeutics IncMLYS▲ Added 5.0%+369K$10M0.11%
GeneDx Holdings CorpWGS▲ Added 262%+151.84K$9.8M0.10%
Inspire Med Systems IncINSP▲ Added 129%+183.7K$9.5M0.10%
Waystar Holding CorpWAY▲ Added 267%+385K$9.3M0.10%
Corvus Pharmaceuticals IncCRVS▲ New+450K$6.6M0.07%
Equillium IncEQ▲ New+3.1M$6.2M0.07%
Bicara Therapeutics IncBCAX▲ Added 4.3%+300K$6M0.06%
4D Molecular TherapeuticsFDMT▼ Reduced 11%−603.43K$5.6M0.06%
Macrogenics IncMGNX▲ New+1.86M$5.4M0.06%
Maplight Therapeutics IncMPLT▲ New+248.29K$5M0.05%
Progyny IncPGNY▼ Sold out−96.63K$2.5M0.03%
Qiagen NVQGEN▼ Sold out−43.98K$2.1M0.02%
Orthopediatrics CorpKIDS▼ Sold out−109.96K$2M0.02%
Health Catalyst IncHCAT▼ Sold out−793.75K$1.9M0.02%
Adicet Bio IncACET▲ Added 25%+234.38K$1.6M0.02%
Evommune IncEVMN▲ Added 1.0%+35.87K$824.6K0.01%
Climb Bio IncCLYM▲ Added 0.06%+7.11K$48.7K0.00%

Holdings at the quarter's end

Peter Kolchinsky holdings, Q1 2026
#StockSectorShare of portfolioValueSharesReported priceHeldSince Q4 2025
1Ascendis Pharma A/SASND · SPONSORED ADRHealth Care24.9%$2.4B10.28M$228.738+ qtrsNo change
2Vaxcyte IncPCVXHealth Care7.07%$666.8M11.47M$58.118+ qtrs▲ Added 7.0%
3Rhythm Pharmaceuticals IncRYTMHealth Care6.14%$579.8M6.67M$86.978+ qtrsNo change
4Tyra Biosciences IncTYRA—4.95%$467.2M12.2M$38.308+ qtrsNo change
5Sionna Therapeutics IncSION—4.21%$397.1M9.91M$40.095 qtrsNo change
6Edgewise Therapeutics IncEWTXHealth Care3.48%$328.5M10.43M$31.508+ qtrsNo change
7Newamsterdam Pharma CompanyNAMS—3.24%$305.7M9.55M$32.018+ qtrsNo change
8
Nuvalent Incno ticker on file
—2.75%$259.6M2.53M$102.453 qtrs▲ Added 35%
9Dianthus Therapeutics IncDNTHHealth Care2.32%$219.2M2.61M$83.928+ qtrs▲ Added 62%
10Mineralys Therapeutics IncMLYS—2.21%$208.4M7.69M$27.098+ qtrs▲ Added 5.0%
11Spyglass Pharma IncSGP—2.20%$207.8M8.02M$25.911 qtrNew
12Wave Life Sciences LtdWVE—2.07%$195.6M26.98M$7.258+ qtrs▲ Added 48%
13Septerna IncSEPN—1.78%$168.1M7M$24.036 qtrsNo change
14Disc Medicine IncIRON—1.66%$156.7M2.45M$63.945 qtrs▲ Added 24%
15Janux Therapeutics IncJANX—1.65%$155.5M11.19M$13.908+ qtrsNo change
16BioCryst Pharmaceuticals IncBCRX—1.60%$150.7M15.83M$9.522 qtrsNo change
17Bicara Therapeutics IncBCAX—1.53%$144.3M7.26M$19.897 qtrs▲ Added 4.3%
18Praxis Precision MedicinesPRAXHealth Care1.28%$120.4M373.79K$322.192 qtrsNo change
19GH Research PLCGHRS—1.14%$107.9M7.68M$14.068+ qtrsNo change
20Zai Lab LtdZLAB · ADR—1.14%$107.4M5.71M$18.811 qtrNew
21Taysha Gene Therapies IncTSHA—1.12%$105.3M23.56M$4.478+ qtrsNo change
22Vor Biopharma IncVOR—1.02%$96.4M5.4M$17.848+ qtrsNo change
23Geron CorpGERN—1.01%$95M63.77M$1.498+ qtrsNo change
24Ars Pharmaceuticals IncSPRY—0.92%$87.2M10.86M$8.038+ qtrsNo change
25Sarepta Therapeutics IncSRPT—0.90%$84.9M3.9M$21.761 qtrNew
26Spyre Therapeutics IncSYREHealth Care0.87%$81.8M1.62M$50.442 qtrsNo change
27Evommune IncEVMN—0.85%$80.3M3.49M$22.992 qtrs▲ Added 1.0%
28Climb Bio IncCLYM—0.82%$77.4M11.3M$6.858+ qtrs▲ Added 0.06%
29Solid Biosciences IncSLDB—0.71%$67.2M9.34M$7.208+ qtrs▲ Added 61%
30Artiva Biotherapeutics IncARTV—0.67%$63.5M9.85M$6.447 qtrsNo change
31Damora Therapeutics IncDMRA—0.66%$62.1M2.4M$25.901 qtrNew
32Xencor IncXNCR—0.63%$59.1M4.9M$12.061 qtrNew
33LB Pharmaceuticals IncLBRX—0.58%$54.5M2.21M$24.663 qtrsNo change
34Jade Biosciences IncJBIO—0.55%$51.6M3.67M$14.054 qtrsNo change
35Acumen Pharmaceuticals IncABOS—0.53%$49.5M20.99M$2.368+ qtrs▲ Added 41%
364D Molecular TherapeuticsFDMT—0.50%$47M5.05M$9.318+ qtrs▼ Reduced 11%
37Fulcrum Therapeutics IncFULC—0.49%$46.4M6.05M$7.678+ qtrsNo change
38Capricor Therapeutics IncCAPR—0.49%$45.8M1.51M$30.402 qtrsNo change
39Century Therapeutics IncIPSC—0.43%$40.1M17.75M$2.261 qtrNew
40Olema Pharmaceuticals IncOLMA—0.41%$38.8M2.6M$14.912 qtrsNo change
41Lenz Therapeutics IncLENZ—0.41%$38.2M4.18M$9.158+ qtrsNo change
42Monopar Therapeutics IncMNPR—0.39%$36.6M667.21K$54.796 qtrsNo change
43Pepgen IncPEPG—0.38%$35.5M20.06M$1.778+ qtrsNo change
44Design Therapeutics IncDSGN—0.34%$31.6M2.97M$10.643 qtrs▲ Added 103%
45Mirum Pharmaceuticals IncMIRMHealth Care0.31%$29.4M318.55K$92.381 qtrNew
46Bioage Labs IncBIOA—0.31%$28.9M1.65M$17.491 qtrNew
47Lexeo Therapeutics IncLXEO—0.30%$28.7M5M$5.742 qtrsNo change
48Assembly Biosciences IncASMB—0.30%$28.3M1.02M$27.753 qtrsNo change
49Rezolute IncRZLT—0.30%$28M9.18M$3.052 qtrsNo change
50Aktis Oncology IncAKTS—0.29%$26.9M1.5M$17.891 qtrNew
51Alx Oncology Holdings IncALXO—0.28%$26.1M13.01M$2.001 qtrNew
52Aclaris Therapeutics IncACRS—0.27%$25.5M6.8M$3.751 qtrNew
53Ovid Therapeutics IncOVID—0.25%$23.8M10.71M$2.222 qtrsNo change
54Nkarta IncNKTX—0.24%$22.8M10.81M$2.118+ qtrsNo change
55Travere Therapeutics IncTVTXHealth Care0.24%$22.2M746.84K$29.711 qtrNew
56Grail IncGRALHealth Care0.24%$22.1M428.27K$51.682 qtrsNo change
57C4 Therapeutics IncCCCC—0.22%$21M8M$2.632 qtrsNo change
58Relmada Therapeutics IncRLMD—0.22%$20.5M2.95M$6.961 qtrNew
59Benitec Biopharma IncBNTC—0.21%$19.7M1.85M$10.652 qtrsNo change
60Bright Minds Biosciences IncDRUG—0.21%$19.3M265K$72.971 qtrNew
61Sutro Biopharma IncSTRO—0.19%$17.8M715.31K$24.911 qtrNew
62Contineum Therapeutics IncCTNM—0.18%$16.9M1.3M$13.063 qtrs▼ Reduced 41%
63Sab Biotherapeutics IncSABS—0.18%$16.9M4.4M$3.833 qtrsNo change
64Inspire Med Systems IncINSP—0.18%$16.8M325.66K$51.583 qtrs▲ Added 129%
65Anteris Technologies GlobalAVR—0.18%$16.7M3M$5.551 qtrNew
66Onkure Therapeutics Inc-AOKUR—0.18%$16.6M4M$4.141 qtrNew
67Hinge Health IncHNGETechnology0.15%$14.1M364.61K$38.562 qtrs▲ Added 355%
68GeneDx Holdings CorpWGS—0.14%$13.5M209.89K$64.224 qtrs▲ Added 262%
69Waystar Holding CorpWAYTechnology0.14%$12.8M529.4K$24.112 qtrs▲ Added 267%
70Helix Acquisition CorpHLXC—0.14%$12.7M1.25M$10.161 qtrNew
71Palisade Bio IncPALI—0.13%$12.5M7.12M$1.752 qtrsNo change
72Acrivon Therapeutics IncACRV—0.12%$11.6M8.34M$1.398+ qtrsNo change
73Atrium Therapeutics IncRNA—0.12%$11.6M864.1K$13.371 qtrNew
74Karyopharm Therapeutics IncKPTI—0.11%$10.7M1.92M$5.571 qtrNew
75Avalo Therapeutics IncAVTX—0.11%$9.9M662.97K$14.937 qtrsNo change
76
Perceptive Cap Solutionsno ticker on file
—0.09%$8.2M750K$10.978+ qtrsNo change
77Adicet Bio IncACET—0.09%$8.1M1.18M$6.818+ qtrs▲ Added 25%
78
Newamsterdam Pharma Co NV-27no ticker on file · WTS
—0.07%$6.7M333.33K$20.048+ qtrsNo change
79Corvus Pharmaceuticals IncCRVS—0.07%$6.6M450K$14.631 qtrNew
80Rani Therapeutics Holdings-ARANI—0.07%$6.2M8.5M$0.73482 qtrsNo change
81Equillium IncEQ—0.07%$6.2M3.1M$2.001 qtrNew
82Werewolf Therapeutics IncHOWL—0.06%$5.6M6.68M$0.83268+ qtrsNo change
83Macrogenics IncMGNX—0.06%$5.4M1.86M$2.891 qtrNew
84Maplight Therapeutics IncMPLT—0.05%$5M248.29K$20.331 qtrNew
85Palatin Technologies IncPTN—0.01%$1.2M70K$17.422 qtrsNo change

By sector

Peter Kolchinsky portfolio by sector, Q1 2026
SectorShare of portfolioValuePositions
Health Care46.9%$4.4B10
Technology0.28%$26.8M2
No sector on file52.9%$5B73

Questions and answers

What did Peter Kolchinsky own in Q1 2026?

RA Capital Management's 13F for Q1 2026 lists 85 positions worth $9.4B. The largest: ASND (24.9%), PCVX (7.1%), RYTM (6.1%), TYRA (5.0%), SION (4.2%).

What did Peter Kolchinsky buy in Q1 2026?

The largest purchases, by the shares bought at the quarter-end price the filing implies: SGP (new, $207.8M), ZLAB (new, $107.4M), SRPT (new, $84.9M), DNTH (added, $83.9M), Nuvalent Inc (added, $67M), WVE (added, $63.6M).

What did Peter Kolchinsky sell in Q1 2026?

The largest sales: Cidara Therapeutics Inc (sold out, $743.4M), Avidity Biosciences Inc (sold out, $623.3M), Arcellx Inc (sold out, $82.6M), BLTE (sold out, $69.2M), IVVD (sold out, $42.3M), MDLN (sold out, $14.1M).

When was this filing made?

RA Capital Management filed its 13F for the quarter ending Mar 31, 2026 on May 15, 2026. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.

Learn

Cite this page

Funkfolio, “Peter Kolchinsky portfolio, Q1 2026: RA Capital Management 13F holdings”, data as of 15 May 2026. https://funkfolio.com/gurus/peter-kolchinsky/2026-q1

Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Mar 31, 2026.

Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Mar 31, 2026, filed May 15, 2026. Changes compare share counts with the filing for Dec 31, 2025; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $9.4B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 8 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.